Khan Sadiya S, Breathett Khadijah, Braun Lynne T, Chow Sheryl L, Gupta Deepak K, Lekavich Carolyn, Lloyd-Jones Donald M, Ndumele Chiadi E, Rodriguez Carlos J, Allen Larry A
Circulation. 2025 May 20;151(20):e1006-e1026. doi: 10.1161/CIR.0000000000001307. Epub 2025 Apr 16.
The growing morbidity, mortality, and health care costs related to heart failure (HF) underscore the urgent need to prioritize its primary prevention. Whereas a risk-based approach for HF prevention remains in its infancy, several key opportunities exist to actualize this paradigm in clinical practice. First, the 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America HF guidelines provided recommendations, for the first time, on the clinical utility of multivariable risk equations to estimate risk of incident HF. Second, the American Heart Association recently developed the PREVENT (Predicting Risk of Cardiovascular Disease Events) equations, which not only enable prediction of incident HF separately, but also include HF in the prediction of total cardiovascular disease. Third, the predominant phenotype of HF risk has emerged as the cardiovascular-kidney-metabolic syndrome. Fourth, the emergence of novel therapies that prevent incident HF (eg, sodium-glucose cotransporter-2 inhibitors) and target multiple cardiovascular-kidney-metabolic axes demonstrate growing potential for risk-based interventions. Whereas the concept of risk-based prevention has been established for decades, it has only been operationalized for atherosclerotic cardiovascular disease prevention to date. Translating these opportunities into a conceptual framework of risk-based primary prevention of HF requires implementation of PREVENT-HF (Predicting Risk of Cardiovascular Disease Events-Heart Failure) equations, targeted use of cardiac biomarkers (eg, natriuretic peptides) and echocardiography for risk reclassification and earlier detection of pre-HF, and definition of therapy-specific risk thresholds that incorporate net benefit and cost-effectiveness. This scientific statement reviews the current evidence for accurate risk prediction, defines strategies for equitable prevention, and proposes potential strategies for the successful implementation of risk-based primary prevention of HF.
与心力衰竭(HF)相关的发病率、死亡率和医疗保健成本不断上升,凸显了对其一级预防进行优先考量的迫切需求。虽然基于风险的HF预防方法仍处于起步阶段,但在临床实践中实现这一模式存在几个关键机遇。首先,2022年美国心脏协会/美国心脏病学会/美国心力衰竭学会HF指南首次就多变量风险方程在估计HF发病风险方面的临床效用提供了建议。其次,美国心脏协会最近开发了PREVENT(预测心血管疾病事件风险)方程,该方程不仅能够单独预测HF发病,还将HF纳入了总心血管疾病的预测中。第三,HF风险的主要表型已成为心血管-肾脏-代谢综合征。第四,预防HF发病的新型疗法(如钠-葡萄糖协同转运蛋白2抑制剂)的出现以及针对多个心血管-肾脏-代谢轴的疗法,显示出基于风险的干预措施具有越来越大的潜力。虽然基于风险的预防概念已经确立了几十年,但迄今为止仅在动脉粥样硬化性心血管疾病预防中得以实施。将这些机遇转化为基于风险的HF一级预防的概念框架,需要实施PREVENT-HF(预测心血管疾病事件风险-心力衰竭)方程,有针对性地使用心脏生物标志物(如利钠肽)和超声心动图进行风险重新分类以及更早地检测HF前期,并且定义纳入净效益和成本效益的特定疗法风险阈值。本科学声明回顾了准确风险预测的当前证据,定义了公平预防的策略,并提出了成功实施基于风险的HF一级预防的潜在策略。